Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.

ABSTRACT: The fully human monoclonal antibody denosumab was approved for treatment of osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces clinically meaningful increases in bone mineral density (BMD) and reduces fracture risk at key skeletal sites. At that time, questions remained regarding the long-term safety and efficacy of this receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor; and with clinical experience, new questions have arisen regarding its optimal use. Here, we examine these questions through the lens of data from the FREEDOM trial program and other studies to determine where denosumab fits in the osteoporosis treatment landscape. Clinical consensus and evidentiary support have grown for denosumab as a highly effective anti-osteoporo

SUBMITTER: Kendler DL 

PROVIDER: S-EPMC8799550 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature